

aflibercept

Medicare Part B Drug Policy

- Medicare coverage is limited to items and services that are reasonable and necessary for the diagnosis or treatment of an illness or injury (and within the scope of a Medicare benefit category).
- Medicare Benefit Policy Manual Pub. 100-02, Chapter 15, Section 50, describes national policy regarding Medicare guidelines for coverage of drugs and biologicals.
- Blue Shield of California (BSC) follows Medicare statutes, regulations, National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and policy articles for determining coverage for Part B drug requests when applicable.
- BSC Medicare Part B Drug Policies will be used when coverage criteria are not fully established
 or there is an absence of any applicable Medicare statutes, regulations, NCDs or LCDs.

Drug Details

USP Category: OPHTHALMIC AGENTS

Mechanism of Action: Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor that binds VEGF-A and PGF, thereby inhibiting the binding and activation of these cognate VEGF receptors

HCPCS:

J0177:Injection, aflibercept hd, 1 mg J0178:Injection, aflibercept, 1 mg

How Supplied:

Eylea:

- 2 mg/0.05 mL solution in a single-dose pre-filled syringe
- 2 mg/0.05 mL solution in a single-dose vial

Vial Kit contains the following Components:

- one Eylea 2 mg/0.05 mL single-dose glass vial
- one 19-gauge × 1½-inch, 5-micron, filter needle for withdrawal of the vial contents
- one 30-gauge × ½-inch injection needle for intravitreal injection
- one 1-mL syringe for administration

Eylea HD:

- 8 mg (0.07 mL of 114.3 mg/mL solution) in a single-dose vial 61755-050-01: Vial Kit with Injection Components
 - 8 mg single-dose glass vial
 - one 18-gauge × 1½-inch, 5-micron, filter needle for withdrawal of the vial contents
 - one 30-gauge × ½-inch injection needle for intravitreal injection
 - one 1-mL syringe for administration

61755-051-01: Vial Only

• 8 mg single-dose glass vial

Condition(s) listed in policy (see coverage criteria for details)

- Diabetic Macular Edema (DME)
- Diabetic Retinopathy
- Macular Edema (ME) Following Central or Branch Retinal Vein Occlusion (RVO)

Blue Shield of California is an independent member of the Blue Shield Association A56538MADD 1024

aflibercept

Effective: 12/01/2024

Y0118 24 675A1 C 10162024

H2819 24 675A1 C Accepted 10212024

- Neovascular (WET) Age-Related Macular Degeneration (AMD)
- Retinopathy of Prematurity (ROP)

Any request for a condition not listed in policy must meet the definition of a medically accepted indication. Section 1861(t)(2)(B) of the Act defines "medically-accepted indication," as any use of a prescription drug or biological product which is approved under the Federal Food, Drug, and Cosmetic Act, or the use of which is supported by one or more citations included (or approved for inclusion) in one or more of the CMS approved compendia.

Special Instructions and Pertinent Information

Provider must submit documentation (such as office chart notes, lab results or other clinical information) to ensure the member has met all medical necessity requirements.

Coverage Criteria

The following condition(s) require Prior Authorization/Preservice:

Diabetic Macular Edema (DME)

Meets medical necessity if all the following are met:

1. Diagnosis only

Covered Doses:

Eylea: 2 mg (0.05 ml) given by intravitreal injection every 25 days Eylea HD: 8 mg given by intravitreal injection every 3-5 weeks for the first three doses, followed by 8 mg once every 7 to 17 weeks

Coverage Period:

Yearly

ICD-10:

E08.3XXX, E09.3XXX, E10.3XXX, E11.3XXX, E13.3XXX

Diabetic Retinopathy

Meets medical necessity if all the following are met:

Diagnosis only

Covered Doses:

Eylea: 2 mg (0.05 ml) given by intravitreal injection every 25 days

Eylea HD: 8 mg given by intravitreal injection every 3-5 weeks for the first three doses, followed by 8 mg once every 7 to 13 weeks

Coverage Period:

Yearly

ICD-10:

E08.3XXX, E09.3XXX, E10.3XXX, E11.3XXX, E13.3XXX

aflibercept

Effective: 12/01/2024

Macular Edema (ME) Following Central or Branch Retinal Vein Occlusion (RVO)

Meets medical necessity if all the following are met:

Request is for Eylea (not Eylea HD)

Covered Doses:

Eylea: 2 mg (0.05 ml) given by intravitreal injection every 25 days

Coverage Period:

Yearly

ICD-10:

H34.8110-8112, H34.8120-8122, H34.8130-8132, H34.8190-8192, H34.8310-8312, H34.8320-8322, H34.8330-8332, H34.8390-8392

Neovascular (WET) Age-Related Macular Degeneration (AMD)

Meets medical necessity if all the following are met:

1. Diagnosis only

Covered Doses:

Eylea: 2 mg (0.05 ml) given by intravitreal injection every 25 days

Eylea HD: 8 mg given by intravitreal injection every 3 - 5 weeks for the first three doses, followed by 8 mg once every 7 to 17 weeks

Coverage Period:

Yearly

ICD-10:

H35.3210-3213, H35.3220-3223, H35.3230-3233, H35.3290-3293

Retinopathy of Prematurity (ROP)

Meets medical necessity if all the following are met:

Request is for Eylea (not Eylea HD)

Covered Doses:

Eylea: 0.4 mg (0.01 ml) given by intravitreal injection every 10 days

Coverage Period:

Yearly

ICD-10:

H35.109

Additional Information

Summary of Evidence

The contents of this policy were created after examining the following resources:

- 1. The prescribing information for Eylea and Eylea HD
- 2. CMS approved compendium in accordance with the accepted compendia ratings listed:
 - a. Micromedex DrugDex Class I, Class IIa, of Class IIb

aflibercept

Effective: 12/01/2024

b. American Hospital Formulary Service-Drug Information (AHFS-DI) - supportive narrative text

Explanation of Rationale:

 Support for FDA-approved indications can be found in the manufacturer's prescribing information.

References

- 1. CMS Benefit Policy Manual. Chapter 15; § 50 Drugs and Biologicals
- 2. Medicare Coverage Database. Available at https://www.cms.gov/Medicare-Coverage-Database/search.aspx
- 3. Social Security Act (Title XVIII) Standard References, Sections: 1862(a)(1)(A) Medically Reasonable & Necessary; 1862(a)(1)(D) Investigational or Experimental; 1833(e) Incomplete Claim; 1861(t) (1) Drugs and Biologicals
- 4. AHFS. Available by subscription at http://www.lexi.com
- 5. DrugDex. Available by subscription at http://www.micromedexsolutions.com/home/dispatch
- 6. Eylea (aflibercept) Prescribing information. Regeneron Pharmaceuticals, Inc., Tarrytown, NY. 12/2023.
- 7. Eylea HD (aflibercept) Prescribing information. Regeneron Pharmaceuticals, Inc., Tarrytown, NY. 12/2023.

Review History

Date of Last Annual Review: 1Q2024 Changes from previous policy version:

New Part B policy

Blue Shield of California Medication Policy to Determine Medical Necessity Reviewed by P&T Committee

The company complies with applicable state laws and federal civil rights laws and does not discriminate, exclude people, or treat them differently on the basis of race, color, national origin, ethnic group identification, medical condition, genetic information, ancestry, religion, sex, marital status, gender, gender identity, sexual orientation, age, mental disability, or physical disability. La compañía cumple con las leyes de derechos civiles federales y estatales aplicables, y no discrimina, ni excluye ni trata de manera diferente a las personas por su raza, color, país de origen, identificación con determinado grupo étnico, condición médica, información genética, ascendencia, religión, sexo, estado civil, género, identidad de género, orientación sexual, edad, ni discapacidad física ni mental. 本公司遵守適用的州法律和聯邦民權法律,並且不會以種族、膚色、原國籍、族群認同、醫療狀況、遺傳資訊、血統、宗教、性別、婚姻狀況、性別認同、性取向、年齡、精神殘疾或身體殘疾而進行歧視、排斥或區別對待他人。

aflibercept

Effective: 12/01/2024